Home
HelpEpic Test Code LAB3569 Methotrexate, Serum
Additional Codes
MML Code: MTHX
LIS Code: MTXTR
Useful For
Determining whether methotrexate is being cleared appropriately and verifying that a nontoxic concentration has been attained following therapy
Method Name
Immunoassay
Reporting Name
Methotrexate, SSpecimen Type
SerumOrdering Guidance
For patients that have received glucarpidase (carboxypeptidase G2) as a high-dose methotrexate rescue therapy, order MTXSG / Methotrexate Post Glucarpidase, Serum.
Shipping Instructions
Ship specimen in amber vial to protect from light.
Specimen Required
Supplies: Sarstedt 5 mL Aliquot Tube (Amber) (T915)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Amber vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Methotrexate is sensitive to fluorescent light; avoid prolonged exposure of specimen to direct light.
2. Serum gel tubes should be centrifuged within 2 hours of collection. Protect from light.
3. Red-top tubes should be centrifuged and serum aliquoted into amber vial within 2 hours of collection.
Specimen Minimum Volume
0.25 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | LIGHT PROTECTED |
| Frozen | 28 days | LIGHT PROTECTED | |
| Ambient | 72 hours | LIGHT PROTECTED |
Reject Due To
| Gross hemolysis | Reject |
Clinical Information
Methotrexate is an antineoplastic agent that inhibits DNA synthesis. The medication exerts its effects through competitive inhibition of the enzyme dihydrofolate reductase thus decreasing the concentrations of tetrahydrofolate essential to the methylation of pyrimidine nucleotides and consequently the rate of pyrimidine nucleotide and ultimately DNA synthesis.
Methotrexate is used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Methotrexate is effective against malignancies characterized by rapid cell proliferation. Intermediate to high doses of methotrexate with leucovorin (citrovorum-factor or folinic acid) rescue to salvage nontumor cells have been used with favorable results in the treatment of osteogenic sarcoma, leukemia, non-Hodgkin lymphoma, lung, and breast cancer.
Methotrexate has the potential for serious toxicity. Patients undergoing methotrexate therapy are closely monitored so that toxic effects are detected promptly.
Reference Values
Nontoxic drug concentration after 72 hours: <0.1 mcmol/L
Interpretation
Serum concentrations of methotrexate are commonly monitored during high-dose therapy (>50 mg/m[2]) to identify the time at which active intervention by leucovorin rescue should be initiated. Criteria for serum concentrations indicative of a potential for toxicity after single-bolus, high-dose therapy are as follows:
-Methotrexate >10 mcmol/L 24 hours after dose
-Methotrexate >1 mcmol/L 48 hours after dose
-Methotrexate >0.1 mcmol/L 72 hours after dose
Cautions
Important: Specimens from patients who have received glucarpidase (carboxypeptidase G2) as a high-dose methotrexate rescue therapy should not be tested with this immunoassay. Methotrexate concentrations should be performed using the liquid chromatography-tandem mass spectrometry method to avoid the reporting of falsely elevated methotrexate values due to an interference that could confuse the efforts of the glucarpidase therapy. After glucarpidase therapy, it can take at least 5 to 7 days before accurate measurements of serum methotrexate can be obtained using an immunoassay.
Report Available
Same day/1 daySpecimen Retention Time
1 weekPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
80204
NY State Approved
YesDay(s) Performed
Monday through Sunday
Forms
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.